Darunavir in treatment-naïve patients. The ARTEMIS study;Darunavir en pacientes naïve: Estudio ARTEMIS

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 10, 2008, Pages 10-13

  Estrada, Vicente ^a   Fuster, Mónica ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Darunavir ritonavir; HIV infection; Lopinavir ritonavir

Indexed keywords

DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SIDE EFFECT; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; GASTROINTESTINAL DISEASES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; VIRAL LOAD;

EID: 75849116323     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)76548-0     Document Type: Article

References (11)

1. R. Ortiz, E. DeJesus, H. Khanlou, E. Voromin, J. Van Lunzen, J. Andrade-Villanueva, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 AIDS 22 2008 1389 1397
2. R.M. Hoetelmans, M.H. Reijers, G.J. Weverling, R.W. Ten Kate, F.W. Wit, J.W. Mulder, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy AIDS 12 1998 111 115
3. V. Sekar, C.V. Abeele, B.V. Vaelen, et al. Pharmacokinetic- pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study 9th International Workshop on Clinical Pharmacology of HIV Therapy New Orleans, LA, USA; April 7-9 2008
4. N. Malan, E. Krantz, D. Neal, K. Kastango, D. Frederick, and M. Mathew Efficacy and safety of atazanavir with and without ritonavir in antiretroviral-naive subjects. BMS089: 48-week results Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections Denver, Colorado, February 2006
5. K.Y. Smith, W.G. Weinberg, and E. DeJesus Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT AIDS Res Ther 5 2008 5 (Pubitemid 351639013)
6. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Updated January 29, 2008. Disponible en: http://www.aidsinfo. nih.gov/guidelines
7. J. Madruga, D. Berger, and M. McMurchie Efficacy and safety of darunavir- ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial Lancet 370 2008 49 58 (Pubitemid 47023100)
8. D. Mildvan, C. Tierney, R. Gross, et al. and the ACTG A5073 Study Team Randomized comparison in treatment-naive patients of once-daily vs twicedaily lopinavir/ritonavir-based ART and comparison of once-daily self-administered vs directly observed therapy Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections Los Angeles, California, February 25-28 2007 (abstract 138)
9. J. Eron Jr., P. Yeni, and J. Gathe Jr. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial Lancet 368 2006 476 482 (Pubitemid 44160731)
10. S. Walmsley, B. Bernstein, and M. King Lopinavir/ritonavir versus nelfinavir for the initial treatment of HIV infection N Engl J Med 346 2002 2039 2046 (Pubitemid 34680595)
11. M.J. Shelton, M.B. Wire, Y. Lou, B. Adamkiewicz, and S.S. Min Pharmacokinetic and Safety Evaluation of High-Dose Combinations of Fosamprenavir and Ritonavir Antimicrob Agents Chemother 50 2006 928 934 (Pubitemid 43327796)